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p-Aminobenzoic acid  (PABA)  not  only reverses sulfonamide inhibition  (2) 
but  also,  in higher  concentrations,  is itself a  chemotherapeutically useful in- 
hibitor of rickettsiae (3-5). The competition with sulfonamides is clearly asso- 
ciated with  the normal metabolic function of PABA;  in contrast,  its mode of 
action  as  a  chemotherapeutic  agent  is  unknown. 
A  key to this problem was provided by the  discovery, based on the  nutri- 
tional  requirement  of  certain  mutants  (quintuple  aromatic  auxotrophs)  of 
Escherichia  toll, that p-hydroxybenzoic acid  (POB)  is an essential metabolite 
in this organism (6)  and is able  to reverse competitively the  inhibition of E. 
coli by its sulfone analogue,  4,41-dihydroxydiphenyl sulfone  (6,  7). The pres- 
ent  communication will report that  POB  exerts a  similar reversing effect on 
inhibition by high concentrations of PABA, which therefore appears to act as 
a  competitive analogue of POB.  A  more limited reversal of PABA inhibition 
is  also  produced  by precursors  of  POB.  In  addition,  it  will  be  shown  that 
analogues of POB exert only a growth-retarding effect, but become completely 
bacteriostatic on addition of L-aspartic acid in exceedingly low concentrations. 
Methods 
Experiments were performed at 37°C. in minimal medium A (8)  with the W strain  of 
E. coIi (ATCC No. 9637), as well as mutants derived from it (quintuple aromatic auxotrophs) 
that require tyrosine, phenylalanine, tryptophan,  PABA, and POB (6, 9). Competition be- 
tween inhibitor and antagonist was studied chiefly  in pour plates containing 50 to 100 bacterial 
cells; the advantages of this method have been discussed elsewhere (10). More conventional 
methods, employing liquid media or streaks on solid media, were also tested for practically 
all the phenomena reported; they yielded similar results, except that higher concentrations 
were required for inhibition. In addition, resistant mutants grew out in liquid media. 
Inhibition  by  PABA;  Synergism  with z-Aspartic  Acid 
Table I  shows that growth of the W  strain of E. coli is slowed by PABA at a 
concentration  of  150  #g./ml.  Bacteriostasis,  however,  is  incomplete,  large 
* Aided by a grant from The Squibb Institute for Medical Research. 
:~ A preliminary report of this work has appeared (1). 
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Inhibition of Wild Type •.  coli by PABA and Aspartic Acid; Reversal by POB or Shikimic 
Acid 
Approximately 50 cells of E. coli (W strain) were poured in 5 ml. of medium A agar, sup- 
plemented asindicated, in Petri dishes (50 ram. diameter). After incubation at 37 ° C., colony 
size was visually estimated, ranging from m (microscopic) and ½ (barely visible) to 4 (large). 
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TABLE II 
Synergism  of Aspartic  Acid  and  Related Compounds  with  PABA  Inhibition 
Experimental conditions as  in  Table  I. 
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colonies  developing by  48  hours.  With  increasing  concentrations of  PABA 
the inhibition becomes more prolonged, but even at 800 #g./ml. small colonies 
appear  by 48  hours,  and at  1600/~g./ml.  they appear  by 5  days. Identical 
results have been obtained with the K-12 strain of E. coll. 
Table I also shows that the addition of aspartic acid converts the retardation 
by PABA into essentially permanent bacteriostasis. In Table II it is seen that 
the  synergism produced by DL-aspartic  acid is complete at  2 ~g./ml.,  while 
some effect is exerted by even lower concentrations3 In contrast, DL-aspartic 
acid  alone  produces  negligible inhibition at  2000  ~g./ml. L-Aspartic  acid  is 
about twice as effective as the racemic mixture, while D-aspartic acid is inac- 
tive. The concentration of aspartic  acid required for synergism is relatively 
independent of the concentration of PABA; conversely, as is seen in Table I, 
the concentration of PABA required for inhibition is not altered by the addi- 
tion of aspartic acid. Synergism with PABA inhibition is also shown, but only 
at higher concentrations, by asparagine and fumaric acid, which probably act 
through conversion to aspartic acid. Succinic,  malic, and cysteic acids showed 
no synergism in concentrations up to 200 #g./ml.  (Table II). 
L-Aspartic acid and asparagine have previously been reported  (11) to pro- 
long  the  growth-retarding  effect of D-serine,  which  interferes  competitively 
with the conversion of/3-alanine to pantothenate (10). As with PABA, syner- 
gism with D-serine is also shown by fumaric acid but not by succinic or cysteic 
acid (12);  in addition, the same concentrations of the several compounds are 
required for synergism with either PABA or D-serine. The resemblance of the 
two  systems suggested  a  possible  connection between  them,  but  none  was 
found: pantothenate failed to eliminate the effect of aspartic acid on PABA 
inhibition,  while  POB  failed  to  overcome  its  effect on D-serine  inhibition. 
The incomplete bacteriostatic effect exerted by PABA is not a  peculiarity 
of this compound, but appears rather to be a property of competitive inhibi- 
tory systems that is revealed by the technique used here, which permits un- 
usually prolonged observation of the interaction between individual cells and 
a relatively constant environment. With this technique sulfathiazole, a classical 
competitive  inhibitor,  showed  a  tenfold  range  between  the  concentrations 
that prevented appearance of visible colonies in 1 and in 5 days. Aspartic acid 
exerted no effect on this inhibition. 
Reversal of PABA Inhibition by POB and Its Precursors 
As is shown in Table I, the inhibitory effect of PABA is overcome in a com- 
petive manner by POB in a concentration about 1/100 that of PABA; delayed 
reversal is produced at an even lower ratio. The  addition of aspartic  acid, 
x  Failure to yield visible  colonies  by 5 days is a practical but not a rigorous  index of com- 
plete bacteriostasis; after 7 days colonies  did appear in the presence of PABA 200 plus  DL- 
aspartic acid 2 #g./ml. (Table III), but not PABA 200 plus DL-aspartic acid 10 #g./ml. BERNARD  D.  DAVIS  247 
despite its synergistic inhibitory effect, does not significantly alter the com- 
petitive ratio. At the lower inhibitory concentrations of PABA (200 #g./ml.) 
the  competitive ratio  is  smaller  (about  1/200),  presumably because  of the 
contribution of POB by the wild type ceils themselves, which synthesize this 
substance in excess  and excrete it  (6).  It can be noted that with increasing 
concentrations of PABA the growth rate is less completely restored to normal 
by POB,  even in  excess;  this  residual  inhibition, presumably due  to  inter- 
ference with other enzyme systems, is not affected by aspartic acid. 
Shikimic  acid  (a  3,4,5-trihydroxycyclohexene-l-carboxylic acid),  a  pre- 
cursor of POB  as well as of several other aromatic metabolites (9,  13), also 
antagonizes  PABA  inhibition,  but  less  effectively than  POB  itself.  Several 
limitations of the reversing effect of shikimic acid are illustrated in Table I: 
it  is  ineffective against  a  moderate  concentration  of  PABA  (400 #g./ml.); 
even when added in excess it only partly restores the growth rate in the presence 
of a minimal inhibitory concentration (200 #g./ml.); its action is impeded by 
aspartic acid. Similar results were obtained with compound X,  ~ a precursor of 
shikimic acid  (9)  recently isolated and identified as a  dehydroshikimic acid 
(14). It is concluded that these precursors, even in excess, can increase to only 
a  limited extent the intracellular concentration of POB in E. coli, since they 
can only approximately double the  concentration of PABA required for in- 
hibition. 
The effect of aspartic  acid on the action of shikimic acid is described in 
greater detail in Table III. DL-Aspartic  acid at 3/~g./ml. partly prevents, and 
at  100  /~g./ml.  nearly permanently prevents,  shikimic  acid  from reversing 
PABA  inhibition.  Furthermore,  shikimic  acid  is  no  more  effective at  100 
#g./ml. than at 1 ~g./ml. On the other hand, aspartic acid does not significantly 
interfere with the reversal of inhibition by POB (Table III), and could be shown 
to have no effect on the quantity of POB required by mutants (unpublished 
observations).  Since aspartic acid could not be shown  to  interfere with  the 
utilization of POB, it appears to interfere with its synthesis from shikimic acid, 
but in a  manner that cannot be competitively overcome by shiklmic acid. It 
seems  unllkely,  however,  that  this  effect of  aspartic  acid  accounts  for  its 
synergism with PABA; the reasons will be discussed in a later section. 
It is of interest to note that shikimic acid also has little capacity to antagonize 
a competitive analogue of another of its metabolic derivatives (9, 13),  PABA. 
Using the minimal concentration of sulfathiazole (1  ~g./ml.)  that produced 
prolonged inhibition of E. coli  under the experimental conditions of Table I, 
we were unable to demonstrate significant reversal  by shikimic acid, even at 
100  /~g./ml., though the  inhibition  was  reversed  completely by 0.3  ~g./ml. 
PABA, and slowly by as little as 0.01/~g./ml. 
Generously provided by Dr. I. I. Salamon of this laboratory. 248  INHIBITION  O~  ESCHERICHIA  COLI 
TABLE III 
I~fsr~ce by Aspartic Aci8 ~th th~ R~'saJ of PABA Inhibi~n by Shikim~ A¢~ 
Experimental  conditions  as  in  Table  I. 
P.~A 
#g./~. 
200 
vI,-Aspa,  r  tic 
acid 
m 
3 
~C 
cc 
3O 
C~ 
~g 
C~ 
lOO 
C~ 
C~ 
C¢ 
POB 
~,g./ml. 
0.5 
2 
0.5 
2 
0.5 
2 
O.S 
2 
Shikimlc acid 
j,g./mL 
1 
lOO 
1 
100 
1 
lOO 
h 
1 
100 
Idsy 
Colony size 
2 days  5 days  7  days 
Inhibition by Re~te.d Compou~s 
The inhibition  of some bacteria  by 4,4'-dihydroxydiphenyl  sulfone  (bis(4- 
hydroxyphenyl)sulfone)  is  not  reversed  by  PABA  (15)  but  is  reversed  by 
POB  (6,  7).  Both  this sulfone  3 and  the hydroxy  analogue s of sulfathiazole 
(N-(2-thiazolyl)-4-hydroxybenzenesulfonamide;  phenosulfazole;  darvisul)  are 
active against E. coli at 100 #g./ml.; they resemble PABA in requiring aspartic 
acid for complete bacteriostasis.  The sulfonamide analogue of POB, p-hydroxy- 
benzenesulfonamide, 4 is inactive in concentrations  up to 1000 ~g./ml., as has 
been reported by other investigators,  p-Chlorobenzoic acid and p-fluorobenzoic 
acid are also inactive at 1000 pg./ml. 
s Provided through the courtesy of the American Cyanamid Co. and E. R. Squibb and Sons. 
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The competition between PABA and POB does not appear to be symmetrical; 
we observed  no inhibition  by POB  in  concentrations  up  to  2000 #g./ml.  At 
20  mg./ml.,  however,  a  bactericidal  effect  on E.  coli has  been  reported  (7). 
In contrast to the relative inactivity of POB,  its esters are used as food pre- 
servatives,  presumably acting as phenolic disinfectants  (16,  17). 
TABLE IV 
Simultaneous Inhibitory  Competition of p-Nitrobemoic Acid with PABA and POB 
Experimental  conditions  as  in  Table  I. 
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Simultaneous Competition of p-Nitrobenzdc Acid witk PABA  and POB 
Table IV shows that p-nitrobenzoic acid  (PNBA) at 50 to 100/~g./ml. pro- 
duces inhibition that is reversed by POB plus PABA, but not by either vitamin 
alone? It must be emphasized that in this experiment,  in contrast to the pre- 
vious ones,  PABA is present  in a  moderate  concentration and is acting as a 
metabolite  rather  than  an  inhibitor. 
As with the other analogues of POB, the anti-POB effect (i.e., the inhibition 
produced in the presence of PABA) is transient and requires aspartic acid for 
s A shmilar double competition was observed with two samples of phenosulfazole but was 
traced  to contamination  of this material  with sulfathiazole, from which it had been manu- 
factured.  PNBA was therefore recrystallized three times from different solvents;  no  change 
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complete bacteriostasis.  The anti-PABA effect (i.e., the inhibition produced in 
the presence of POB)  is also only transient; this property has been explained 
by the observed  reduction of PNBA to its own reversing  agent, PABA,  by 
the  bacteria  (18, 19). The  anti-PABA effect  is  markedly prolonged by DL- 
aspartic acid (Table IV)  or L-aspartic  acid; D-aspartic  acid is inactive. Since 
L-aspartic acid does not affect inhibition by a stable analogue of PABA, such 
as  sulfathiazole  (unpublished  data),  its  effect  on  the  anti-PABA action of 
PNBA appears  to imply that it interferes  with the reduction of PNBA  to 
PABA. No connection is obvious between this property of L-aspartic acid and 
its synergism with POB analogues or D-serine. 
Inhibition of POB-Requiring Mutants 
Since wild type E. coli synthesizes and excretes POB  (6), a mutation that 
blocked POB synthesis would be expected to increase the sensitivity to inhibi- 
tion by POB analogues. As no mutant with a single requirement for POB has 
been  isolated,  quintuple  aromatic  auxotrophs  (83-1, 170-27)  were  tested 
in the presence of adequate quantities of their requirements  (including POB 
0.01  t~g./ml.).  For  these  mutants  the  minimal inhibitory concentration of 
PABA was 10/zg./ml., in contrast to 150 #g./ml. for wild type. Even greater 
differences between mutant and wild type (up to 25-fold) were obtained with 
other POB analogues; this result is not unexpected, for it is known that PABA 
in moderate concentrations slowly satisfies the POB  requirement of the mu- 
tants (6), and hence would tend to antagonize itself. 
With these mutants it was also possible to observe POB-reversible inhibition 
of growth by 100 to 300  /zg./ml. of p-hydroxybenzenesulfonamide,  p-chloro- 
benzoic acid,  and p-fluorobenzoic acid,  which  have been noted above  to be 
inactive against wild type at 1000 ~g./ml. 
The synergistic action of L-aspartic acid was observed with the mutants as 
with wild type. 
Inhibition of Rickettsiae 
The competition between POB and PABA observed with E. coli has led to 
similar experiments  with rickettsiae, kindly performed by Dr. J.  C. Snyder. 
A preliminary report of the reversal by POB  of the rickettsiostatic action of 
PABA in chick embryos and mice has been published  (20). 
DISCUSSION 
Following the announcement of POB  as a bacterial vitamin required  by a 
mutant (6), our attention was called to an earlier report by Levaditi et al.  (7) 
that this compound  reversed  inhibition of E. coli by 4,4"-dihydroxydiphenyl 
sulfone.  This  work  was  unfortunately overlooked  because  of  an  abstract  6 
that misquoted the reversing agent as PABA rather than POB. 
* Chem. Abstr., 1945, 89, 3320. BERNARD  D.  DAVIS  251 
The mechanism of inhibition of E.  coli by PABA has been shown in  the 
present paper to depend on competition with POB. PABA is known to inhibit 
not only this organism (21) but also other bacteria, fungi (22, 23), and rickett- 
siae.  Of particular chemotherapeutic interest is the reversal of its rickettsio- 
static action by POB in vivo  (20). 
PABA has  the unusual property of acting metabolically in  three different 
ways: as an essential metabolite, required by certain mutants in a low concen- 
tration (0.005 #g./ml.); as a replacement for, and presumably source of, POB 
in quintuple  aromatic auxotrophs  (6,  9)  at a  higher concentration (0.1  to  1 
#g./ml.); and as a competitive inhibitor of POB utilization, in either wild type 
or mutants, at even higher concentrations (150 #g./ml. for wild type, 10 #g./ml. 
for POB-requiring mutants). This last effect implies that POB cannot be formed 
from high concentrations of PABA to an extent that can compensate for the 
inhibitory effect of PABA itself. The combined role of PABA as both competi- 
tor and source of POB finds precedent in the similar relation between p-nitro- 
benzoic  acid  and  PABA  (18,  19)  and  possibly  between  aspartic  acid  and 
fl-alanine (10). 
A further consequence of the close structural resemblance between PABA and 
POB  is the simultaneous competition of p-nitrobenzoic acid with both these 
metabolites. PABA alone has been reported to reverse inhibition of E. coli by 
p-nitrobenzoic acid (19), but it is hardly surprising that the residual inhibition 
due to competition with POB should have been overlooked, since this effect is 
transient in the absence of aspartic acid,  and is not readily demonstrated in 
liquid media as employed in that investigation. 
The inhibition of a "sulfonamide-requiring" mutant of Neurospora by PABA 
(24)  probably involves a  mechanism quite different from the direct competi- 
tion with POB reported here, since it requires only an exceedingly low concen- 
tration of PABA,  and PABA can be replaced as inhibitor by methionine, a 
product of PABA metabolism (25). 
L-Aspartic acid, and related compounds that readily give rise to it, have been 
shown to be synergistic with all the available competitors of POB. This rela- 
tion has several remarkable features. First, aspartic acid is active in a concentra- 
tion  (lgg./ml.)  that  one might expect to be quickly metabolized,  7 yet high 
concentrations of this  compound  alone (> 1000 #g./ml.)  are  not  inhibitory. 
Secondly,  aspartic  acid  substantially  eliminates  the  whole  range  of partial 
growth inhibition by POB analogues, causing a  sharp transition from lack of 
inhibition at one concentration (e.g.,  100 #g./ml.  PABA)  to permanent bac- 
It should be emphasized that the extraordinary sensitivity  to aspartic acid was detected 
with inocula of discrete cells scattered in solid media. It could also be demonstrated in liquid 
media with very small inocula (10  3  cells). With ordinary inocula (10 t cells), however,  growth 
occurred without appreciable inhibition by PABA or synergism by aspartic acid. The cause 
of this growth was shown to include the outgrowth of resistant mutants, and possibly also 
metabolic elimination of the inhibitors and excretion of POB. 252  INHIBITION 0~'  ESCHERICHIA  COLI 
teriostasis at a slightly higher  concentration (150/~g./ml. PABA). This effect 
parallels the fact that a large number of quintuple aromatic auxotrophs have a 
requirement for POB that is only partial but becomes complete on the addition 
of L-aspartic acid in concentrations similar to those required for synergism with 
PABA (unpublished observations). Thirdly,  the synergistic  effect of aspartic 
acid  does not  significantly  change  the  minimal  inhibitory  concentration  of 
POB analogues or their competitive ratio with POB. 
The mechanism of the aspartic acid effect is not clear. Since aspartic acid does 
not interfere with reversal of PABA inhibition by POB, but does interfere with 
its reversal by shikimic acid,  a precursor of POB, aspartic acid appears to im- 
pede the synthesis of POB from shikimic acid, though it is unable alone to block 
this reaction in wild type. It is unlikely,  however, that this effect of aspartic 
acid entirely accounts for its synergism with POB analogues,  for aspartic acid 
is required in very low concentration for prolongation of growth inhibition  by 
these analogues, but in higher concentration for prolonged interference  with the 
reversal of this inhibition  by shikimic acid. Furthermore, a genetic block in the 
synthesis of POB causes a 15- to 25-fold increase in sensitivity to inhibition  by 
POB analogues,  yet aspartic acid does not cause even a 2-fold increase  in the 
sensitivity  of  wild  type.  One  therefore  wonders  whether  the  aspartic  acid 
effect may not involve a  more complex mechanism than  the simple  competi- 
tions under consideration.  In particular,  it seems possible that aspartic acid, 
though not increasing  the quantitative requirement of a genetically or chemi- 
cally blocked cell for POB, may directly or indirectly interfere with some POB- 
requiring  reaction, but only when this reaction is being slowed through  sub- 
optimal supply of POB or its products. These considerations  may well apply to 
the very similar  synergism of L-aspartic  acid with D-serine, which blocks the 
conversion of j3-alanine to pantothenic acid (10) ; the mechanism here is equally 
obscure. There is no indication of any direct metabolic connection between the 
two systems. 
Research with bacterial mutants in this laboratory has been based in part 
(13) on the hope of finding metabolites that are peculiar to microorganisms  and 
absent from the animal host;  such compounds would be rational models for 
the synthesis of analogues designed  to be selectively toxic to microorganisms, 
and hence chemotherapeutically useful. The thought that POB might be such 
a useful model arose when liver extract was found to lack significant  quantities 
of  this  compound  (6). The  relatively high  concentrations  of available  POB 
analogues required for inhibition  of E. coli, however, offer little hope that these 
compounds will have chemotherapeutic value against organisms  whose POB 
metabolism quantitatively resembles  that  of E. coli.  On the other hand,  the 
proved value of PABA in rickettsial infections  verifies  the anticipation  that 
POB might be a  useful chemotherapeutic model,  and shows that some para- 
sites are adequately susceptible to inhibition in dvo by at least one of its ana- BERNARD  D.  DAVIS  253 
logues. Other analogues of POB, and possibly of aspartic acid, therefore seem 
to merit further chemotherapeutic investigation. 
It is a pleasure to acknowledge  the excellent technical  assistance of Virginia C. Littau and 
Elizabeth S. Mingioli. 
SUMMARY 
p-Aminobenzoic acid  (PABA)  exerts three metabolic effects on E.  coli:  it 
acts as a normal vitamin at low concentrations, as a source of another vitamin, 
p-hydroxybenzoic acid (POB),  at moderate  concentrations, and as  a  growth 
inhibitor at high concentrations (IS0 to 1600 #g./ml.). The inhibition is com- 
petitively reversed by POB in 1/100 the concentration of PABA. The inhibition 
is also reversed to a limited extent by shikimic acid and compound X, precur- 
sors of POB. 
p-Nitrobenzoic acid is an inhibitory competitor of both POB and PABA. 
The retardation of growth produced by PABA and other competitive ana- 
logues of POB  (p-nitrobenzoic acid; 4,4'-dihydroxydiphenyl sulfone; pheno- 
sulfazole) is converted to complete bacteriostasis by the addition of l.-aspartic 
acid in a  remarkably low  concentration  (l  #g./ml.), without change in  the 
competitive ratio with POB. The mechanism underlying this synergism is not 
clear. 
In contrast to wild type, mutants that require POB not only are inhibited 
by much lower concentrations of the above analogues, but also show inhibition 
by weaker competitors  of  POB  such  as  p-hydroxybenzenesulfonamide, p- 
chlorobenzoic acid, and p-fluorobenzoic acid. 
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